Becker R E, Colliver J A, Markwell S J, Moriearty P L, Unni L K, Vicari S
Department of Psychiatry, Southern Illinois University School of Medicine, Springfield, USA.
Alzheimer Dis Assoc Disord. 1998 Mar;12(1):54-7. doi: 10.1097/00002093-199803000-00009.
Forty-seven patients with probable Alzheimer disease (AD) completed a 6-month double-blind study to compare metrifonate with placebo. The Alzheimer Disease Assessment Scale cognitive subscale score of the metrifonate group treated to a 50-70% inhibition of red blood cell acetylcholinesterase activity differed significantly from the placebo group score by 1.8 points (p < 0.03) due to a deterioration in cognitive performance in the placebo group (p < 0.01). Statistically significant deterioration also occurred in the Mini-Mental State Examination scores (p < 0.01) in the placebo-treated group. Adverse effects were uncommon and did not require adjustment of the dose of metrifonate or discontinuation of treatment. These findings extend our previous report of a favorable effect of metrifonate on cognitive symptoms in AD by showing clinical, not only statistical, significance.
47名疑似阿尔茨海默病（AD）患者完成了一项为期6个月的双盲研究，以比较敌百虫与安慰剂的效果。在红细胞乙酰胆碱酯酶活性被抑制50 - 70%的敌百虫治疗组中，阿尔茨海默病评估量表认知子量表得分与安慰剂组得分相比有显著差异，相差1.8分（p < 0.03），这是由于安慰剂组认知功能恶化（p < 0.01）所致。接受安慰剂治疗组的简易精神状态检查表得分也出现了具有统计学意义的恶化（p < 0.01）。不良反应并不常见，无需调整敌百虫剂量或停止治疗。这些发现不仅在统计学上，而且在临床上都具有显著意义，扩展了我们之前关于敌百虫对AD认知症状有良好效果的报告。
